Get the Stockscreener App
9.265
3.75%
0.335
Fibrogen Inc stock is traded at $9.265, with a volume of 14,757.
It is up +3.75% in the last 24 hours and up +10.03% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$8.93
Open:
$9.0059
24h Volume:
14,757
Relative Volume:
0.44
Market Cap:
$37.54M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-3.1621
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
+6.49%
1M Performance:
+10.03%
6M Performance:
+65.15%
1Y Performance:
-44.44%
1-Day Range:
$8.8588
$9.33
1-Week Range:
$8.5001
$9.33
52-Week Range:
$4.85
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
9.28 | 36.13M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.92 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.55 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.75 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.69 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.75 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
Quarterly Earnings: Is FibroGen Inc stock a buy before product launchesJuly 2025 Review & Weekly Momentum Picks - moha.gov.vn
FibroGen shares advance after roxadustat earns orphan drug status - MSN
How FibroGen Inc. stock reacts to inflationary pressuresSwing Trade & Real-Time Buy Zone Alerts - Улправда
Published on: 2025-12-20 23:42:14 - Улправда
Why FibroGen Inc. (1FG0) stock attracts HNW investorsRecession Risk & Reliable Breakout Stock Forecasts - Улправда
Why FibroGen Inc. stock is a must watch in 2025July 2025 Selloffs & Precise Buy Zone Identification - DonanımHaber
Is FibroGen Inc. stock a buy before product launchesJuly 2025 Price Swings & Weekly Stock Breakout Alerts - DonanımHaber
FibroGen Q3 2025 Earnings Preview - MSN
Published on: 2025-12-19 15:46:05 - Улправда
Will FibroGen Inc. stock outperform international peers2025 Market Trends & Safe Capital Preservation Plans - Улправда
Published on: 2025-12-18 12:26:14 - Улправда
Is FibroGen (NASDAQ:FGEN) A Risky Investment? - simplywall.st
FDA grants orphan drug designation to FibroGen’s roxadustat for MDS By Investing.com - Investing.com Nigeria
FDA grants orphan drug designation to FibroGen’s roxadustat for MDS - Investing.com India
FibroGen stock rises after roxadustat receives Orphan Drug Designation By Investing.com - Investing.com Nigeria
FibroGen stock rises after roxadustat receives Orphan Drug Designation - Investing.com India
FibroGen (FGEN) Gains FDA Orphan Drug Status for Roxadustat - GuruFocus
Roxadustat granted orphan drug designation for the treatment of myelodysplastic syndromes by the U.S. FDA - marketscreener.com
FibroGen Receives FDA Orphan Drug Designation for Roxadustat in Myelodysplastic Syndromes, Phase 3 Protocol Set for Q4 2025 Submission - Quiver Quantitative
Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration - The Manila Times
Roxadustat Granted Orphan Drug Designation for the - GlobeNewswire
Market Review: Will FibroGen Inc stock keep outperforming rivals2025 Risk Factors & Breakout Confirmation Trade Signals - moha.gov.vn
FibroGen Investor Suit Dismissed Following $28.5 Million Deal - Bloomberg Law News
Can FibroGen Inc. (1FG0) stock deliver strong annual returnsSell Signal & AI Powered Market Entry Strategies - Newser
Will FibroGen Inc. (1FG0) stock outperform global peers2025 Valuation Update & Safe Capital Growth Stock Tips - Newser
FibroGen (FGEN) Stock Analysis Report | Financials & Insights - Benzinga
Is FibroGen Inc. (1FG0) stock overpriced at current multiplesDividend Hike & Weekly Momentum Picks - Newser
How FibroGen Inc. (1FG0) stock reacts to fiscal policiesWeekly Trade Review & Weekly Watchlist for Hot Stocks - Newser
How dovish Fed policy supports FibroGen Inc. (1FG0) stockAnalyst Downgrade & Entry and Exit Point Strategies - Newser
How supply shortages influence FibroGen Inc. (1FG0) stockSell Signal & Weekly Return Optimization Alerts - Newser
Is FibroGen Inc. (1FG0) stock a top hedge fund pick2025 Fundamental Recap & Smart Allocation Stock Tips - Newser
FibroGen, Inc. to Present at Oppenheimer Movers in Rare Disease Summit on December 11, 2025 - Quiver Quantitative
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - GlobeNewswire
Why FibroGen Inc. (1FG0) stock is trending on social mediaJuly 2025 PreEarnings & AI Enhanced Execution Alerts - moha.gov.vn
FibroGen started at buy by H.C. Wainwright - MSN
What valuation multiples suggest for FibroGen Inc. stockWeekly Trade Analysis & Verified Momentum Watchlists - newser.com
Can FibroGen Inc. (1FG0) stock ride next bull market cycle2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
Why FibroGen Inc. stock remains resilientPortfolio Return Summary & Real-Time Buy Signal Alerts - newser.com
Can FibroGen Inc. (1FG0) stock deliver consistent EPS growthJuly 2025 Decliners & Weekly Top Gainers Alerts - newser.com
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrogen Inc Stock (FGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
| Schoeneck James A | Director |
Jun 30 '25 |
Buy |
5.07 |
23,567 |
119,485 |
39,666 |
| Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):